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ABSTRACT
Diagnosis of non cirrhotic portal fibrosis was considered when the following criteria were fulfilled
evidence of portal hypertension (oesophageal varices, hypersplenism, ascites, or increased hepatic venous
pressure gradient), Doppler ultrasound showing patent portal and hepatic veins, and liver biopsy showing
sign of cirrhosis. Non cirrhotic portal fibrosis clinically characterized by splenomegaly, anemia, portal
hypertension, and histopathological examination portal tract showing fibrosis and sclerosis. Portal
hypertension are most caused by a cirrhotic liver (85%), there are only a few reports on non cirrhotic portal
hypertension, mostly in Japan and India. We reported a case of non cirrhotic portal fibrosis in young male.
The clinical complications of portal hypertension are variceal bleeding and pancytopenia due to hypersplenism.
Variceal band ligation and splenectomy were performed. The patient showed good clinical response.
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INTRODUCTION
The standard of normal portal venous pressure is
5 - 10 mmHg. Portal hypertension is defined as pressure
that exceeds 10 mmHg.1-4  Cirrhosis is the most common
cause of portal hypertension in the United States (85%).
Other causes of portal hypertension are portal vein
obstruction, infection, pancreatitis,  abdominal trauma,
portal vein thrombosis or idiopathic. Idiopathic portal vein
thrombosis may develop in a variety of hypercoagulable
states, including polycthemia vera, essential
trombocythemia, deficiency of protein C, protein S or
antithrombin III.3 Hepatic vein thrombosis and hepatic
venoocclusive disease are relatively infrequent cause of
portal hypertension. Non cirrhotic portal fibrosis accounts
for only a few cases of portal hypertension. There are
reports on non-cirrhotic portal hypertension in India and
Japan, and in Indonesia it is presumed to be less than
5%.2, 3
Causes of portal hypertension can be classified as
increased resistance to flow and increase portal blood
flow. Increasing resistance can cause by at pre-hepatic
obstruction (portal vein obstruction), intrahepatic
obstruction, and posthepatic obstruction.
Non cirrhotic fibrosis of the liver can be distinguished
from cirrhosis by the absence of hepatocellular damage
and lack of nodular regenerative activity, but there are
still manifestations of portal hypertension. There are three
variants of Idiopathic Portal Hypertension or Non
Cirrhotic Portal Fibrosis (NCPF) as follows:
Diagnosis of NCPF was considered when
the following criteria were fulfilled: evidence of portal
hypertension (oesophageal varices, hypersplenism,
ascites, or increased hepatic venous pressure gradient).
Doppler ultrasound showing patent portal and hepatic
veins, liver biopsy showing no cirrhosis.6 Non cirrhotic
portal fibrosis (NCPF) clinically characterized by
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splenomegaly, anemia, portal hypertension and 
histologically by portal tract fibrosis and sclerosis. NCPF  
is a common cause of portal hypertension in India.6  
 The major clinical manifestations of portal  
hypertension include haemorrhage from gastro- 
esophageal varices, splenomegaly with hypersplenism,  
ascites, and acute and chronic hepatic encephalopathy.3  
Treatments are directed to specific manifestations of portal  
hypertension, and sometimes to reduce the pressure in  
the portal venous system. Both surgery and β-adrenergic  
blockade can reduce the portal hypertension. The focus  
on treatments are lowering the portal pressure which can  
be measured in wedge hepatic vein pressure < 12 mmHg,  
or by 20% from baseline. If wedged hepatic pressure is  
not feasible, reduction of 25% heart rate is reasonable.3  
 This case report of a young male 17 years old with  
a blood vomiting, caused by oesophageal varices, and  
hypersplenism caused by massive splenomegaly. Both  
were complications of NCPF. Ligation and splenectomy  
were performed and the results were good condition  
after these procedure. 
 
CASE ILLUSTRATION 
Male, 17 years old was admitted to our hospital on  
12th of December 2004 with chief complaint of  
hematemesis 3 months prior to admission. Patient had no  
fever. He also complained of general weakness. There 
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was no complaint of cough or night sweat. 
He had history of hematemesis and melena since  
4 months and 3 months before admission. He was first  
hospitalized at other hospital. In this hospital ultra sound  
examination and endoscopy were done. The ultra sound’s  
result was chronic liver disease and splenomegaly.  
Endoscopy revealed oesophageal varices grade III-IV.  
He was then referred to our hospital for variceal ligation.  
 Four years before, patient felt swelling on his left  
upper abdomen. He did not feel any pain, although  
the size of the swelling was getting bigger. Since  
the patient did not consider his ill seriously, he did not see  
the doctor. 
He and his family have no history of liver disease, and  
or icteric, no history of malaria, or travelling to endemic  
area. He is experiencing his social life as a high school  
student. His father has died several years ago. Never use  
any drugs, alcohol, traditional medicine, nor herbal  
medicine. 
On physical examination we found good general  
condition, under nutrition with BMI 16.7 kg/m2. Pressure  
was 120/80 mmHg, pulse rate 90 x/m, respiratory rate  
20 x/m, temperature 36°C. His conjunctiva did not look  
pale, and not icteric, there is no abnormality found in heart  
and lungs examination. From abdominal examination we  
found no abnormality except the spleen was enlarged  
(Schufner V) and there was no abdominal tenderness. 
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Table1. Causes of Portal Hypertension5 
Increased Resistance Below 
Prehepatic (portal vein 
obstruction) 
 Congenital atresia or 
stenosis 
 Thrombosis of portal vein 
 Thrombosis of splenic vein 
 Extrinsic compression (for 
example tumours) 
 
Hepatic 
 Cirrhosis 
 Acute alcoholic liver disease 
 Congenital hepatic fibrosis 
 Idiopathic portal hypertension 
(hepatoportal sclerosis) 
 Idiopathic portal hypertension 
(hepatoportal sclerosis) 
 Schitosomiasis 
Posthepatic 
 Budd-Chiari syndrome 
 Constrictive pericarditis 
Increased Portal Blood Flow 
 Arterial-portal venous fistula 
Increased splenic flow 
 
Table 2.  Some Causes of Non cirrhotic Hepatic Fibrosis3 
Idiopathic portal hypertension (non cirrhotic portal fibrosis, Banti's syndrome); three variants: 
Intrahepatic phlebosclerosis and fibrosis 
Portal and splenic vein sclerosis 
Portal and splenic vein thrombosis 
Schistosomiasis ("pipe-stem" fibrosis with presinusoidal portal hypertension) 
Congenital hepatic fibrosis (may be associated with polycystic disease of liver and kidneys) 
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Laboratory results revealed hemoglobin 9.2 g/dL
(13-16), hematocryte 29.6% (40-48), leukocyte 3,000/µL
(5,000-10,000), trombocyte 57,000/µL (150,000-400,000
µL), MCV 76.7 fL MCH 23.8 pg MCHC 31.1 g/dL, ALT
12 U/L (0-35), AST 24 U/L (0-36), normal urine analysis,
albumin level of 4.2 g/dL (3,4-4,8), globulin level of 3 g/dL
(1.8-3.9), total bilirubin  level of 1.0 mg/dL (0.0-1.0), direct
bilirubin level of 0.3 mg/dL (0.0-0.3), indirect bilirubin level
of 0.7 mg/dL (0.0-0.7), sodium concentration of 141 mEq/
L (135-147), potassium concentration of 3.92 mEq/L
(3.5-5.5), chloride 106 mEq/L (100-106), BUN 17 mg/dL
(10-50), creatinin 0.5 mg/dL (0.5-1.5), random blood
glucose 105 mg/dL. Chest X-ray examination was normal.
There were several problems in this patient, first
oesophageal varices with history of variceal bleeding.
The second problem was splenomegaly with pancytopenia,
which considered as hypersplenism. These problems were
considered as one entity of portal hypertension. Portal
hypertension in this patient was considered as non cirrhotic
portal hypertension. We have further using diagnostic
procedure to determine the etiology of portal hypertension.
We plan to use ultrasound with doppler, liver biopsy
examination of hepatitis B marker, hepatitis C marker.
We plan to use bone marrow puncture to confirm
hypersplenism as an etiology of pancytopenia
Bone marrow puncture and biopsy were done, and
the result has shown no abnormality in his bone marrow,
and it was considered as hypersplenism. Ultrasound and
Doppler were used and the results were splenomegaly,
normal liver’s size, and thrombus in splenic vein and   portal
vein. Hepatitis C marker (anti HCV) was negative and
hepatitis B (HBsAg, anti HBc IgM, HBV DNA) were
also negative. Liver biopsy revealed portal fibrosis, liver
fibrosis stadium 2, and weak positive on immunoperoxyde
staining.
Due to portal vein thrombus and splenic vein
thrombus we did measure of protein C, protein S,
coagulation study and the result were protein C 158.6%
(70 - 140) and protein S  120% (70 - 123), dimer
1,500 ng/mL (0 - 300), fibrinogen 176 mg/dL, (200 - 400),
prothrombin time (PT) 17.3 second (11 - 14) activated
partial thrombin time (aPTT) 40.6 second (25.6 - 35.2).
Portal hypertension in this patient were treated with
pharmacological propanolol 2 x 10 mg and isosorbide
mononitrate 2 x 10 mg. Blood pressure 110/70 mmHg
and heart rate was 70 x/m after propanolol and isosorbide
mononotrate. We plan band ligation due to oesophageal
varices. We plan to apply splenectomy procedure due to
hypersplenism.
During splenectomy operation, liver biopsy, and lien
biopsy were taken during the operation, and
histopathological examination was done.
The histopathological result was fibrosis liver grade 3, no
sign of metastases and positive for viral hepatitis B.
Histopathological of spleen was considered as
fibrocongestive spleen.
There is no complication during and after
the operation. After operation patient’s condition was
stable. His final blood test after operation was
haemoglobin 11 g/dL (13-16), hematocryt 35.2%  (40-48),
leukocyte 9,500 u/L, thrombocyte 710,000/uL (150,000 -
400,000). The patient was discharged from hospital in
stable condition and had regular visit at hepatology and
gastroenterology outpatient clinic.
DISCUSSION
Male patient, 17 years old, with history of hematemesis
and caused by oesophageal varices bleeding. His
problem was portal hypertension and  the manifestations
are oesophageal varices and splenomegaly. Complications
were variceal bleeding and hypersplenism. He was
admitted due to these complications.
Diagnosis of portal hypertension is portal pressure that
exceeds 10 mmHg. Measuring the portal vein
pressure can be done directly or indirectly.1 Direct
 measurement is performed by inserting a catheter into
the portal vein or one of it branches. Indirect
measurement is performed by inserting a catheter into
antecubital or femoral vein, and then advance to the small
hepatic vein, the pressure is subtracted from free
hepatic venous pressure to intra abdominal pressure.
Indirect method is safe and simple than direct procedure
but it may not accurate if portal flow block before it enter
the sinusoids.7 Portal hypertension clinically can be
revealed by the appearance of splenomegaly, ascites,
encephalopathy, and or oesophageal varices.1,3,7 CO2
weged hepatic venography can make distinction to
presinusoidal portal hypertension and sinusoidal portal
hypertension.8
Portal hypertension in this patient was based on
clinical features. The clinical manifestations were
oesophageal varices, splenomegaly, and thrombosis
portal vein, thrombosis splenic vein. We did not measure
portal vein pressure because we think it would not change
treatment in this patient.
Most portal hypertension conditions have underlying
cirrhosis liver. However, we  were doubtful this patient
had cirrhotic portal hypertension because his general
condition was good except slightly undernourished. There
were no signs of cirrhosis found such as erythema
palmaris, spider nevi, ascites, or collateral vein. His
albumin serum and also other liver function test were
normal. Histopathological on his liver showed that portal
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fibrosis and fibrosis liver grade 3. Cirrhosis as a cause of
portal hypertension can be excluded in this condition.
Non cirrhotic portal fibrosis are clinically
characterized by splenomegaly, anemia and portal
hypertension, and histologically by portal tract fibrosis and
sclerosis.9-10 Diagnosis of non cirrhotic portal
hypertension was considered  when following criteria
fulfilled evidence of portal hypertension, Doppler
ultrasound showing patent portal and hepatic veins, no
cirrhosis from liver biopsy, and exclusion of conditions
causing cirrhosis  such as chronic viral hepatitis, alcoholic
liver disease, non alcoholic steatohepatitis, obesity.11
Therefore this patient was diagnosed non cirrhotic portal
fibrosis.
The Doppler ultrasonography had shown that this
patient had thrombosis at the portal vein and splenic vein.
Thrombosis at the portal vein and or splenic vein as a
causative in portal hypertension is still controversial.9,12
Portal vein thrombosis are associated with systemic or
local infections (e.g. cholangitis, phlebitis), cirrhotic,
hepatocarcinoma, hypercoagulable (protein C, protein S,
antithrombin III deficiency). Portal vein thrombosis
reported in India was idiopathic, regarding to normal
anticoagulant natural level.13 Protein C and protein S level
this patient is normal, prothrombin time is normal,
therefore we concluded that portal vein thrombosis was
secondary to portal hypertension or portal fibrosis.
We found this patient had non cirrhotic portal fibrosis
based on evidence of portal hypertension, oesophageal
varices, and splenomegaly, no sign of eritema  palmaris-
spider naevi, normal liver function on blood test
(transaminases, albumin), and portal fibrosis on
histopathological. There are number of hypotheses have
been proposed for the ethiopathogenesis; infection,
exposure of chemicals or trace metals, immunologic or
immunogenetic. Umbilical sepsis bacterial infections and
diarrhoeal episodes in infancy and early childhood are
likely to lead to portal pyemia, pylephlebitis, resulting in
thrombosis, sclerosis and obstruction of small and medium
sized portal vein radicals.14 Hepatitis B marker was
negative in this patient, while the histopathological showed
hepatitis B. We considered that possible cause of portal
fibrosis was non specific bacteria infections.
Clinical complications of portal hypertension are
gastrointestinal bleeding, hepatic encephalopathy, ascites,
spontaneous bacterial peritonitis, and hepatopulmonary
syndrome.1 Patient’s managements depend on
complication of portal hypertension. This patient had
oesophageal varices bleeding, and hypersplenism.
The key management issues in patients with NCPF are
gastrointestinal bleeding and hypersplenism.14
The management of this patient was focused on these
complications with band ligation endoscopic, and
splenectomy.
Treatment strategies for oesophagastric varices are
pharmacologic therapy, endoscopic therapy, tamponade,
decompression surgical, devascularization operation and
liver transplantation.7 Propanolol and isosorbide
mononitrate as pharmacological treatment were given to
lowering the portal pressure. β-blocker (propanolol) as
primary prophylaxis had shown a significant
reduction in incidence of first variceal haemorrhage.
β-blocker are indicated in all patients who are high risk of
variceal haemoerhage. The risk are HVPG >  12 mmHg,
red sign on varices, child class, continued alcohol abuse,
varices size.1 Combination of propanolol and isosorbide
mononitrate is effective in lowering portal pressure.15
Patient admitted was not in the variceal bleeding,
therefore pharmacologic therapy, and then band ligation
was performed. Propanolol 10 mg twice daily, and
isosorbide mononitrate 20 mg twice daily, were given and
his heart rate was reducing about 20%. Propanolol are
safe and effective as the first treatment of choice.16-18
Combination of propanolol and isosorbide mononitrate
needs further evaluation, because this combination have
not been confirmed in NCPF patients.18
Oesophageal varices in NCPF are rarely requiring
surgical intervention. Transjugular intrahepatic porto
systemic shunt (TIPS) procedure has been reported to be
effective in idiopathic portal hypertension, however TIPS
has been done in a small number NCPF patients.
Generally the studies have shown lower incidence of
recurrent bleeding in TIPS, but higher rates of
encephalopathy were reported in TIPS.7,13,16,17 TIPS
currently is not recommended for the routine prevention
of rebleeding.17 TIPS cannot be performed due to portal
vein thrombosis.17
Surgery is an effective alternative treatment to
endoscopic therapy. Surgery is also indicated for patients
with symptomatic hypersplenism, spontaneous bleeding
or severe anemia requiring transfusion or splenic infarcts.14
Devascularization procedures have the components of
splenectomy, gastric and oesophageal devascularization,
with the goal of reduced blood flow to oesophageal
varices.7
Endoscopic ligation is the first line procedure in
the management of variceal bleeding in cirrhotic because
it is more effective and safer.16,17 Ligation was performed,
but recurrent bleeding occurred, then another ligation was
done. Splenectomy procedure was treatment of choice in
this patient because of recurrent pancytopenia due to
hypersplenism.
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